PURPOSE: The purpose of this study was to assess women's knowledge about tamoxifen, to examine the frequency of tamoxifen usage and other preventive measures in BRCA1/2 mutation carriers, and to document women's concerns about taking tamoxifen for chemoprevention. METHODS: One hundred and twenty five women with known BRCA1 or BRCA2 mutation and with no prior diagnosis of breast or ovarian cancer were identified through the records of two large cancer genetics clinics. These women had been counseled about their cancer risk and various preventive options were discussed. At a time from two to 110 months following disclosure session, a questionnaire was sent by mail. Women were asked about their current and past use of tamoxifen, their knowledge of risks and benefits, their desire for additional information, and their experience with other preventive measures. RESULTS: Eighty-one of 125 eligible women returned the questionnaire (64.8%). Ten women (12.3%) had used tamoxifen and eight women had used raloxifene (9.9%). Twenty-two women (27.2%) had undergone prophylactic mastectomy and 54 women (66.7%) had had an oophorectomy. Twelve women (14.8%) did not recall discussing tamoxifen. Thirty-five women (58.3%) said that their doctors had not provided them with sufficient information about tamoxifen to consider its use. Fear of side-effects was the most common reason for not taking tamoxifen. CONCLUSION: Although tamoxifen appears to be effective in preventing breast cancer in women with a BRCA1 or BRCA2 mutation, few women now take the drug compared to those who choose other preventive measures including surgery. Health care providers should provide accurate information about the risks and benefits of tamoxifen to allow women to make informed decisions.
PURPOSE: The purpose of this study was to assess women's knowledge about tamoxifen, to examine the frequency of tamoxifen usage and other preventive measures in BRCA1/2 mutation carriers, and to document women's concerns about taking tamoxifen for chemoprevention. METHODS: One hundred and twenty five women with known BRCA1 or BRCA2 mutation and with no prior diagnosis of breast or ovarian cancer were identified through the records of two large cancer genetics clinics. These women had been counseled about their cancer risk and various preventive options were discussed. At a time from two to 110 months following disclosure session, a questionnaire was sent by mail. Women were asked about their current and past use of tamoxifen, their knowledge of risks and benefits, their desire for additional information, and their experience with other preventive measures. RESULTS: Eighty-one of 125 eligible women returned the questionnaire (64.8%). Ten women (12.3%) had used tamoxifen and eight women had used raloxifene (9.9%). Twenty-two women (27.2%) had undergone prophylactic mastectomy and 54 women (66.7%) had had an oophorectomy. Twelve women (14.8%) did not recall discussing tamoxifen. Thirty-five women (58.3%) said that their doctors had not provided them with sufficient information about tamoxifen to consider its use. Fear of side-effects was the most common reason for not taking tamoxifen. CONCLUSION: Although tamoxifen appears to be effective in preventing breast cancer in women with a BRCA1 or BRCA2 mutation, few women now take the drug compared to those who choose other preventive measures including surgery. Health care providers should provide accurate information about the risks and benefits of tamoxifen to allow women to make informed decisions.
Authors: Jeffrey R Botkin; Ken R Smith; Robert T Croyle; Bonnie J Baty; Jean E Wylie; Debra Dutson; Anna Chan; Heidi A Hamann; Caryn Lerman; Jamie McDonald; Vickie Venne; John H Ward; Elaine Lyon Journal: Am J Med Genet A Date: 2003-04-30 Impact factor: 2.802
Authors: J P Struewing; P Hartge; S Wacholder; S M Baker; M Berlin; M McAdams; M M Timmerman; L C Brody; M A Tucker Journal: N Engl J Med Date: 1997-05-15 Impact factor: 91.245
Authors: C Lerman; C Hughes; R T Croyle; D Main; C Durham; C Snyder; A Bonney; J F Lynch; S A Narod; H T Lynch Journal: Prev Med Date: 2000-07 Impact factor: 4.018
Authors: T R Rebbeck; A M Levin; A Eisen; C Snyder; P Watson; L Cannon-Albright; C Isaacs; O Olopade; J E Garber; A K Godwin; M B Daly; S A Narod; S L Neuhausen; H T Lynch; B L Weber Journal: J Natl Cancer Inst Date: 1999-09-01 Impact factor: 13.506
Authors: Kelly Metcalfe; Henry T Lynch; Parviz Ghadirian; Nadine Tung; Ivo Olivotto; Ellen Warner; Olufunmilayo I Olopade; Andrea Eisen; Barbara Weber; Jane McLennan; Ping Sun; William D Foulkes; Steven A Narod Journal: J Clin Oncol Date: 2004-06-15 Impact factor: 44.544
Authors: U Veronesi; P Maisonneuve; A Costa; V Sacchini; C Maltoni; C Robertson; N Rotmensz; P Boyle Journal: Lancet Date: 1998-07-11 Impact factor: 79.321
Authors: Laura L Reimers; Parijatham S Sivasubramanian; Dawn Hershman; Mary Beth Terry; Heather Greenlee; Julie Campbell; Kevin Kalinsky; Matthew Maurer; Ramona Jayasena; Rossy Sandoval; Maria Alvarez; Katherine D Crew Journal: Breast J Date: 2015-04-16 Impact factor: 2.431
Authors: Jacek Gronwald; Andre Robidoux; Charmaine Kim-Sing; Nadine Tung; Henry T Lynch; William D Foulkes; Siranoush Manoukian; Peter Ainsworth; Susan L Neuhausen; Rochelle Demsky; Andrea Eisen; Christian F Singer; Howard Saal; Leigha Senter; Charis Eng; Jeffrey Weitzel; Pal Moller; Dawna M Gilchrist; Olufunmilayo Olopade; Ophira Ginsburg; Ping Sun; Tomasz Huzarski; Jan Lubinski; Steven A Narod Journal: Breast Cancer Res Treat Date: 2014-06-21 Impact factor: 4.872
Authors: J Abugattas; M Llacuachaqui; Y Sullcahuaman Allende; A Arias Velásquez; R Velarde; J Cotrina; M Garcés; M León; G Calderón; M de la Cruz; P Mora; R Royer; J Herzog; J N Weitzel; S A Narod Journal: Clin Genet Date: 2014-10-28 Impact factor: 4.438
Authors: Angela Fagerlin; Brian J Zikmund-Fisher; Vijayan Nair; Holly A Derry; Jennifer B McClure; Sarah Greene; Azadeh Stark; Sharon Hensley Alford; Paula Lantz; Daniel F Hayes; Cheryl Wiese; Sarah Claud Zweig; Rosemarie Pitsch; Aleksandra Jankovic; Peter A Ubel Journal: Breast Cancer Res Treat Date: 2010-02 Impact factor: 4.872
Authors: Karin M Landsbergen; Judith B Prins; Yvonne J L Kamm; Han G Brunner; Nicoline Hoogerbrugge Journal: Fam Cancer Date: 2010-06 Impact factor: 2.375
Authors: Kelly A Metcalfe; Parviz Ghadirian; Barry Rosen; William Foulkes; Charmaine Kim-Sing; Andrea Eisen; Peter Ainsworth; Doug Horsman; Christine Maugard; Diane Provencher; André Robideaux; Dawna Gilchrist; Albert Chudley; Edmond G Lemire; Susan Armel; Amy Finch; Ping Sun; Steven A Narod Journal: Open Med Date: 2007-08-13